MAPK pathway inhibitors rescue lethal phenotypes in a BRAF gain-of-function Drosophila melanogaster model

Abstract

Mutant BRAF is the leading oncogene in melanoma and is found in close to 50% of all melanoma patients (Cancer_Genome_Atlas_Network, 2015). The oncogenic capacity of the BRAFV600E mutation has also been demonstrated in a murine melanoma model (Dankort et al., 2009). This mutation causes the activation of the mitogen-activated protein kinase (MAPK) pathway, which involves BRAF kinase and downstream mitogen-activated extracellular signal-regulated kinases 1/2 (MEK1/2) and extracellular signal-regulated kinases 1/2 (ERK1/2).

This article is protected by copyright. All rights reserved.